VOR BIOPHARMA INC. - Schedule 13D Filing

This filing concerns Vor Biopharma Inc. and the acquisition of its securities by ForGrowth III PA B.V. and its affiliates, collectively referred to as the "Reporting Persons". The Reporting Persons acquired securities through a June 2025 Securities Purchase Agreement and a December 2025 Securities Purchase Agreement. The June 2025 agreement involved the purchase of Pre-Funded Warrants, which were later adjusted due to a reverse stock split. The Reporting Persons exercised some of these warrants, acquiring shares of common stock. The December 2025 agreement led to the purchase of additional shares of common stock. Wouter Joustra, a General Partner at Forbion Capital, was appointed to the Issuer's board of directors on December 18, 2025. The Reporting Persons intend to review their investment and may engage in discussions regarding various strategic actions concerning the Issuer. They collectively hold 9.99% of the outstanding common stock, subject to a beneficial ownership limitation.